Nektar Therapeutics (NKTR) stock
NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$34.42−1.49 (-4.15%)
Close on Nov 18, 2026Market cap $1.18BP/E –Yield –
Nektar Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Nektar Therapeutics's revenue for the twelve months ending Dec 31, 2025 was $55.23M, down 43.9% year over year. For fiscal 2025 it was $55.23M, down 43.9% from the year before. Over ten years it grew -13.3% a year on average. The highest annual figure on record is $1.19B in fiscal 2018.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.23M | -43.9% |
| FY2024 | Dec 31, 2024 | $98.43M | +9.2% |
| FY2023 | Dec 31, 2023 | $90.12M | -2.1% |
| FY2022 | Dec 31, 2022 | $92.06M | -9.7% |
| FY2021 | Dec 31, 2021 | $101.91M | -33.4% |
| FY2020 | Dec 31, 2020 | $152.92M | +33.4% |
| FY2019 | Dec 31, 2019 | $114.62M | -90.4% |
| FY2018 | Dec 31, 2018 | $1.19B | +287.8% |
| FY2017 | Dec 31, 2017 | $307.71M | +86.0% |
| FY2016 | Dec 31, 2016 | $165.44M | -28.3% |
| FY2015 | Dec 31, 2015 | $230.78M | +15.0% |
| FY2014 | Dec 31, 2014 | $200.71M | +34.8% |
| FY2013 | Dec 31, 2013 | $148.92M | +83.4% |
| FY2012 | Dec 31, 2012 | $81.19M | +13.6% |
| FY2011 | Dec 31, 2011 | $71.48M | -55.1% |
| FY2010 | Dec 31, 2010 | $159.04M | +121.1% |
| FY2009 | Dec 31, 2009 | $71.93M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $21.81M | -25.3% |
| Q3 FY2025 | Sep 30, 2025 | $11.79M | -51.1% |
| Q2 FY2025 | Jun 30, 2025 | $11.18M | -52.4% |
| Q1 FY2025 | Mar 31, 2025 | $10.46M | -51.7% |
| Q4 FY2024 | Dec 31, 2024 | $29.18M | +22.1% |
| Q3 FY2024 | Sep 30, 2024 | $24.12M | -0.1% |
| Q2 FY2024 | Jun 30, 2024 | $23.49M | +14.6% |
| Q1 FY2024 | Mar 31, 2024 | $21.64M | +0.2% |
| Q4 FY2023 | Dec 31, 2023 | $23.89M | +8.5% |
| Q3 FY2023 | Sep 30, 2023 | $24.14M | +2.2% |
| Q2 FY2023 | Jun 30, 2023 | $20.50M | -5.0% |
| Q1 FY2023 | Mar 31, 2023 | $21.59M | -13.0% |
| Q4 FY2022 | Dec 31, 2022 | $22.02M | -11.9% |
| Q3 FY2022 | Sep 30, 2022 | $23.63M | -5.2% |
| Q2 FY2022 | Jun 30, 2022 | $21.59M | -23.8% |
| Q1 FY2022 | Mar 31, 2022 | $24.82M | +5.0% |
| Q4 FY2021 | Dec 31, 2021 | $25.01M | +6.6% |
| Q3 FY2021 | Sep 30, 2021 | $24.92M | -17.0% |
| Q2 FY2021 | Jun 30, 2021 | $28.33M | -42.0% |
| Q1 FY2021 | Mar 31, 2021 | $23.65M | -53.2% |
| Q4 FY2020 | Dec 31, 2020 | $23.46M | -30.7% |
| Q3 FY2020 | Sep 30, 2020 | $30.03M | +2.8% |
| Q2 FY2020 | Jun 30, 2020 | $48.85M | +109.5% |
| Q1 FY2020 | Mar 31, 2020 | $50.57M | +79.2% |
| Q4 FY2019 | Dec 31, 2019 | $33.86M | -15.0% |
| Q3 FY2019 | Sep 30, 2019 | $29.22M | +5.2% |
| Q2 FY2019 | Jun 30, 2019 | $23.32M | -97.9% |
| Q1 FY2019 | Mar 31, 2019 | $28.22M | -25.8% |
| Q4 FY2018 | Dec 31, 2018 | $39.83M | -58.3% |
| Q3 FY2018 | Sep 30, 2018 | $27.76M | -81.8% |
| Q2 FY2018 | Jun 30, 2018 | $1.09B | +3044.7% |
| Q1 FY2018 | Mar 31, 2018 | $38.02M | +53.7% |
| Q4 FY2017 | Dec 31, 2017 | $95.47M | +154.9% |
| Q3 FY2017 | Sep 30, 2017 | $152.93M | +320.9% |
| Q2 FY2017 | Jun 30, 2017 | $34.59M | +5.6% |
| Q1 FY2017 | Mar 31, 2017 | $24.73M | – |
| Q4 FY2016 | Dec 31, 2016 | $37.45M | – |
| Q3 FY2016 | Sep 30, 2016 | $36.34M | – |
| Q2 FY2016 | Jun 30, 2016 | $32.77M | – |
See a number that looks wrong?